Loading clinical trials...
Loading clinical trials...
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Who Progressed or Are Resistant to Hypomethylating Agents
Conditions
Interventions
Eltrombopag
Locations
1
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Start Date
April 6, 2011
Primary Completion Date
November 3, 2017
Completion Date
November 3, 2018
Last Updated
November 7, 2022
NCT05070845
NCT06533098
NCT07039422
NCT07007962
NCT07492693
NCT07048249
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions